ClinicalTrials.gg
RecruitingNCT07404644Updated Feb 23, 2026

An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)

An observational study in Von Willebrand Disease (vWD), sponsored by Takeda. Recruiting at 1 site in Japan. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by Takeda · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
13
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in von Willebrand Diseases by Takeda — 3 open to participants now, 3 under way, 2 of them phase 3. von Willebrand Diseases · Takeda.

Started
2026
the only one that year
Observational
4 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in von Willebrand Diseases by Takeda, this one is the only one that started in 2026, is one of 4 observational ones, and was the 13th registered.

von Willebrand Diseases

96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.

Browse von Willebrand Diseases studies →

Open to participants now

3 of the 13 studies in von Willebrand Diseases by Takeda are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 23 von Willebrand Diseases studies recruiting now, 15 (65%) set no upper age limit and 8 (35%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in von Willebrand Diseases by Takeda, or all of them as a file.
02

Study summary

This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD).

The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa (rVWF).

During the study, pediatric participants with vWD will be administered with rVWF under routine normal practice. The investigators will evaluate adverse events due to rVWF for 1 year from the start of drug administration.

The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.

03

Conditions studied

  • Von Willebrand Disease (vWD)

Keywords

  • Von Willebrand Disease (vWD)
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The population of this study are all participants who meet the inclusion/exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Under 18 years old with vWD.
  • Participants who are treated with rVWF for the purpose of hemostatic treatment and management during bleeding episodes or perioperative periods.
  • Participants who have prescription or administration after the approval date of rVWF for pediatric use in Japan.

Exclusion criteria

Exclusion Criteria :

- Patients who are participating in clinical trials of rVWF.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
13 participants (estimated)
Patient registry
No

Groups and cohorts

  • vonicog alfa (rVWF) Group

    Participants with Von Willebrand Disease (vWD) who received vonicog alfa (rVWF) in accordance with package insert.

    Drug: vonicog alfa (rVWF)

Interventions

  • DrugVonicog alfaStudies of Vonicog alfaVonicog alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    rVWF administered by intravenous injection.

    Also known as: Vonvendi Intravenous, Recombinant von Willebrand Factor (rVWF), TAK-577

06

What researchers measure

Primary outcomes

  1. Number of Participants who Experience at Least One Adverse Drug Reactions (ADRs)

    Adverse Event (AE) refers to any undesirable medical occurrence in a patient administered a drug, regardless of causal relationship. This includes any unfavorable or unintended sign (including abnormal laboratory findings), symptom, or disease occurring during administration, regardless of causal relationship. Adverse drug reaction (ADR) refers to AE related to administered drug.

    Time frame: Up to 1 year

Secondary outcomes

  1. Hemostatic Efficacy Assessed by Hemostatic Efficacy Rating Scale

    Hemostatic efficacy for bleeding episodes will be assessed by a predefined 4-point rating scale (Excellent, Good, Moderate, None).

    Time frame: 1 year

  2. Hemostatic Efficacy during Perioperative Periods Assessed by Hemostatic Efficacy Rating Scale

    Hemostatic efficacy during perioperative periods will be assessed by a predefined 4-point rating scale (Excellent, Good, Moderate, None).

    Time frame: 1 year

  3. Number of Infusions per Bleeding Episode

    Time frame: 1 year

  4. Number of Infusions during Perioperative Periods

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Takeda selected site
    Tokyo, Tokyo, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2031, 63 months after the start.

Of 24 observational studies under von Willebrand Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 97. This study's planned 63 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 11, 2026
StartActual
Feb 19, 2026
Primary completionEst.
May 30, 2031
CompletionEst.
May 30, 2031
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07404644
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Feb 19, 2026
Primary completion
May 30, 2031 (estimated)
Completion
May 30, 2031 (estimated)
Last update
Feb 23, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion